Studying Anakinra to Reduce Secondary Brain Damage After Spontaneous Haemorrhagic Stroke
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Spontaneous intracerebral haemorrhage (sICH) is the deadliest stroke subtype yearly affecting
over 6000 patients in the Netherlands. Treatment options are very limited. Inflammation plays
a vital role in the development of sICH-related secondary brain injury (SBI). Within 4 hours
after sICH onset, blood components and thrombin induce the release of cytokines and other
inflammatory molecules, with subsequent microglial activation, blood brain barrier (BBB)
damage and the formation of perihaematomal oedema (PHO). Among the released cytokines,
interleukin 1 beta (IL-1β) has a pivotal role. Recombinant human interleukin-1 receptor
antagonist (IL-1Ra, anakinra) effectively antagonizes IL-1β through competitive binding to
the IL-1 receptor. Anakinra is available for treatment of rheumatoid arthritis, other
inflammatory diseases and has been studied in acute sepsis. We hypothesize that anakinra
safely reduces SBI after sICH, and that is effect is dose-dependent.
Objective: To determine the effect of high-dose versus low-dose anakinra compared to standard
medical management on oedema extension distance (OED) determined with MRI on day 7±1. Second,
to study the safety profile of anakinra. Furthermore, to assess its effect on 1) serum
inflammatory markers IL-1β, IL-6, hsCRP, neutrophil and total white blood cell counts at day
1, 3 and 7 compared to baseline; 2) DCE-MRI measurement of BBB transfer constant (Ktrans) on
day 7±1, and; 3) to estimate an effect on functional outcome in patients with sICH.
Study design: Multicentre, prospective, randomized, three-armed (1:1:1) trial with open label
treatment and blinded end-point assessment (PROBE design) .
Study population: 75 patients with supratentorial sICH admitted within 8 hours after symptom
onset.
Intervention: Patients will receive anakinra in either a high dose (loading dose 500mg i.v.,
followed by infusion with 2mg/kg/h over 3 days; n=25) or in a low dose (loading dose 100mg
s.c.., followed by subcutaneous administration of 100mg twice a day for 3 days; n=25),
started within 8 hours of symptom onset. The control group (n=25) will receive standard
medical management.
Main study parameters/endpoints: Primary objective is to test whether anakinra reduces
subacute perihaematomal oedema after sICH, measured as OED on MRI at day 7±1.